Cost sharing, benefit design, and adherence: The case of multiple sclerosis

Advances in Health Economics and Health Services Research

Volumn 22, Issue , 2010, Pages 175-193

  Dor, Avi ^a   Lage, Maureen J ^a   Tarrants, Marcy L ^a   Castelli Haley, Jane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; EMPLOYER; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; REIMBURSEMENT; RISK ASSESSMENT; TREATMENT OUTCOME; COST; DATA BASE; ECONOMICS; MALE; MIDDLE AGED;

ADULT; COST SHARING; DATABASES AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; REIMBURSEMENT MECHANISMS;

EID: 77955009301     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S0731-2199(2010)0000022011     Document Type: Article

References (48)

1. Baker, C. A. (2004). Cost sharing in medical insurance plans, 31 March. Available at http://www.bls.gov/opub/cwc/content/cm20040326ar01p1.stm. Accessed on 5 October 2009.
2. Blais, L., Couture, J., Rahme, E., & LeLorier, J. (2003). Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance. Health Policy, 64(2), 163-172. (Pubitemid 36407673)
3. Bound, J., Jaeger, D. A., & Baker, R. M. (1995). Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. Journal of the American Statistical Association, 90(430), 443-450.
4. Bymark, L., & Waite, K. (2001). Prescription drug use and expenditures in California: Key trends and drivers. Oakland, CA: California HealthCare Foundation.
5. Capozza, K. (2008). First-dollar coverage for chronic disease care: can it save money and improve patient outcomes? UC Berkeley Center for Labor Research and Education Policy Brief, UC Berkeley Labor Center, September. Available at http://laborcenter.berkeley.edu/healthcare/chronic-disease- coverage08.pdf.
6. Charlson, M. E., Pompei, P., Ales, K. L., & Mackenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373-383. (Pubitemid 17055592)
7. Christian-Herman, J., Emons, M., & George, D. (2004). Effects of generic-only drug coverage in a Medicare HMO. Health Affairs (Millwood), July/December, Suppl., Web exclusives, W455-W68.
8. Cole, J. A., Norman, H., Weatherby, L. B., & Walker, A. M. (2006). Drug copayment and adherence in chronic heart failure: Effect on cost and outcomes. Pharmacotherapy, 26(8), 1157-1164. (Pubitemid 44167823)
9. Cooper, J., Hall, L., Penland, A., Krueger, A., & May, J. (2009). Measuring medication adherence. Population Health Management, 12(1), 25-30.
10. D'Hoore, W., Sicotte, C., & Tilquin, C. (1993). Risk adjustment in outcome assessment: The Charlson comorbidity index. Methods of Information in Medicine, 32, 382-387. (Pubitemid 24001924)
11. Dor, A., & Encinosa, W. (2004). Does cost sharing affect compliance? The case of prescription drugs. NBER Working Paper series, Working Paper no. 10738. National Bureau of Economic Research, Cambridge, MA, August. Available at http://www.nber.org/papers/w10738
12. Encinosa, W. (2002). Pharmacy benefit design options available to employers. Expert Review of Pharmacoeconomics and Outcomes Research, 2(4), 389-396.
13. First DataBank, Inc. (2007). Wholesale acquisition cost, November. Available at http://www.firstdatabank.com/Products/price-point-rx.aspx. Accessed on November 2007.
14. Fraser, C., Morgante, L., Hadjimichael, O., & Vollmer, T. (2004). A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. Journal of Neuroscience Nursing, 36(3), 120-129.
15. Frohman, E. M., Frohman, T. C., Zee, D. S., McColl, R., & Galetta, S. (2005). The neuroophthalmology of multiple sclerosis. The Lancet Neurology, 4(2), 111-121.
16. Gibson, T. B., Ozminkowski, R. J., & Goetzel, R. Z. (2005). The effects of prescription drug costs sharing: A review of the evidence. The American Journal of Managed Care, 291, 2344-2350.
17. Goldman, D. P., Joyce, G. F., Escarce, J. J., Pace, J. E., Solomon, M. D., Laouri, M., Landsman, P. B., & Teutsch, S. M. (2004). Pharmacy benefits and the use of drugs by chronically ill. The Journal of the American Medical Association, 291(19), 2344-2350. (Pubitemid 38656301)
18. Harris, B. L., Stergachis, A., & Ried, L. D. (1990). The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care, 28(10), 907-917.
19. Herndon, R. M., Rudick, R. A., Munschauer, F. E., Mass, M. K., Salazar, A. M., Coats, M. E., Labutta, R., Richert, J. R., Cohan, S. L., Genain, C., Goodkin, D., Toal, M., & Riester, K. (2005). Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Multiple Sclerosis, 11(4), 409-419. (Pubitemid 40984235)
20. Ivanova, J. I., Birnbaum, H. G., Heish, M., Yu, A. P., Seal, B., van der Molen, T., Emani, S., Rosiello, R. A., & Colice, G. L. (2008). Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. The American Journal of Managed Care, 14(12), 801-809.
21. Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., Alam, J. J., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownschedle, C. M., Coats, M. E., Cohan, S. L., Doughtery, D. S., Kinkel, R. P., Mass, M. K., Munschauer, F. E., Priore, R. L., Pullicino, P. M., Scherokman, B. J., & Whitham, R. H. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39(3), 285-294. (Pubitemid 26100751)
22. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., Vollmer, T., Weiner, L. P., Wolinsky, J. S., & the Copolymer 1 Multiple Sclerosis Study Group. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology, 45(7), 1268-1276.
23. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., Vollmer, T., Weiner, L. P., Wolinsky, J. S., & the Copolymer 1 Multiple Sclerosis Study Group. (1998). Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology, 50(3), 701-708.
24. Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H., Miller, D. H., Montalban, X., Barkhof, F., Radu, E., Metzig, C., Bauer, L., Lanius, V., Sandbrink, R., & Pohl, C. (2009). Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-Year active treatment extension of the phase 3 Benefit trial. The Lancet Neurology, 8(11), 987-997.
25. Kobelt, G., Berg, J., Atherly, D., & Hadjimichael, O. (2006). Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology, 66(11), 1696-1702. (Pubitemid 43964625)
26. Lafata, J. E., Cerghet, M., Dobie, E., Schultz, L., Tunceli, K., Reuther, J., & Elias, S. (2008). Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. Journal of the American Pharmacists Association, 48(6), 752-757.
27. Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996). Therapeutic expectations of patients with multiple sclerosis among initiating interferon beta-1b: Relationship to adherence to treatment. Multiple Sclerosis, 2(5), 222-226. (Pubitemid 126701610)
28. Mohr, D. C., Likosky, W., Boudewyn, A. C., Marietta, P., Dwyer, P., Van der Wende, J., & Goodkin, D. E. (1998). Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Multiple Sclerosis, 4(6), 487-489. (Pubitemid 29042155)
29. Murphy, N., Confavreux, C., Haas, J., Konig, N., Roullet, E., Sailer, M., Swash, M., Young, C., the Cost of Multiple Sclerosis Study Group, & Merot, J-L. (1998). Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Journal of Neurology, Neurosurgery, and Psychiatry, 65, 460-466. (Pubitemid 28438873)
30. National Multiple Sclerosis Society. (2009). About MS: who gets MS? Available at http://www.nationalmssociety.org. Accessed on May 19.
31. Noonan, C. W., Kathman, S. J., & White, M. C. (2002). Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology, 58, 136-138. (Pubitemid 34041953)
32. Ozminkowski, R. J., Marder, W. D., Hawkins, K., Wang, S., Stallings, S. C., Finkelstein, S. N., Sinskey, A. J., & Wierz, D. (2004). The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clinical Therapeutics, 26(8), 1341-1354. (Pubitemid 39420318)
33. Page, R. L., Barton, P., & Nair, K. (2008). Effect of cost-sharing for prescription medications on health outcomes in older adults: A critical review of the literature and potential implications for managed care. The Consultant Pharmacist, 23(1), 44-54.
34. Parkin, D., Jacoby, A., McNamee, P., Miller, P., Thomas, S., & Bates, D. (2000). Treatment of multiple sclerosis with interferon beta: An appraisal of cost-effectiveness and quality of life. Journal of Neurology, Neurosurgery, and Psychiatry, 68(2), 144-149. (Pubitemid 30245835)
35. Pilote, L., Beck, C., Richard, H., & Eisenberg, M. J. (2002). The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. Canadian Medical Association Journal, 167, 246-252. (Pubitemid 34920559)
36. Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S., & Amato, M. P. (2008). Long-term adherence to interferon beta therapy in relapsing remitting multiple sclerosis. European Neurology, 59(3-4), 131-135. (Pubitemid 351301255)
37. PRISMS Study Group. (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. The Lancet, 352(9139), 1498-1504.
38. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. (2001). PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology, 56(12), 1620.
39. Smith, D. G., & Kirking, D. M. (1992). Impact of consumer fees on drug utilisation. Pharmaco Economics, 2(4), 335-342.
40. Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43(6), 521-530. (Pubitemid 40847288)
41. Solomon, M. D., Goldman, D. P., Joyce, G. F., & Escarce, J. J. (2009). Cost sharing and the initiation of drug therapy for the chronically ill. Archives of Internal Medicine, 169(8), 740-748.
42. Staiger, D., & Stock, J. H. (1997). Instrumental variables regression with weak instruments. Econometrica, 65(3), 557-586. (Pubitemid 127466159)
43. Stuart, B., & Grana, J. (1998). Ability to pay and the decision to medicate. Medical Care, 36(2), 202-211. (Pubitemid 128454310)
44. Tamblyn, R., Laprise, R., Hanley, J. A., Abrahamowicz, M., Scott, S., Mayo, N., Hurley, J., Grad, R., Latimer, E., Perreault, R., McLeod, P., Huang, A., Larochelle, P., & Mallet, L. (2001). Adverse events associated with prescription drug cost-sharing among poor and elderly persons. The Journal of American Medical Association, 384(4), 421-429. (Pubitemid 32097260)
45. The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1 b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology, 43(4), 655-661.
46. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology, 45(7), 1277-1285.
47. Tremlett, H., Ven der Mei, I., Pittas, F., Blizzard, L., Paley, G., Dwyer, T., Taylor, B., & Ponsonby, A. L. (2008). Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 17(6), 565-576. (Pubitemid 351982762)
48. Whetten-Goldstein, K. (1998). A comprehensive assessment of the cost of multiple sclerosis in the United States. Multiple Sclerosis, 4(5), 419-425. (Pubitemid 28515352)